Cure My Disease

Don't miss your cure!

 Log in / Sign up

Continued EryDex treatment studied in rare neurological disorder

NCT ID NCT06664853

Terminated Disease control Sponsor: Quince Therapeutics S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the disease but to manage its symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATAXIA TELANGIECTASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ataxia telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATAXIA TELANGIECTASIA

Contacts and locations

Locations

  • Cincinnati Children's Hospital, Division of neurology

    Cincinnati, Ohio, 45229, United States

  • Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology

    Copenhagen, Denmark, 2100, Denmark

  • Great Ormond Street Hospital for Children, Zayed Centre for Research

    London, United Kingdom, WC1N 1DZ, United Kingdom

  • Hospital Universitari Vall d'Hebron, Department of pediatric neurology

    Barcelona, Spain, 08035, Spain

  • Hospital Universitario La Paz, Department of pediatric neurology

    Madrid, Spain, 28046, Spain

  • IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases

    Frankfurt am Main, Hesse, 60596, Germany

  • Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic

    Warsaw, 04-736, Poland

  • MedPolonia sp zoo

    Poznan, 60-693, Poland

  • Nottingham Children's Hospital, Queen's Medical Center, Children's neurology

    Nottingham, United Kingdom, NG7 2UH, United Kingdom

  • Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening

    Oslo, Norway, 0372, Norway

  • Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health

    Roma, Italy, 00161, Italy

  • Saint Peter's University Hospital, Inc.

    New Brunswick, New Jersey, 08901, United States

  • Spedali Civili di Brescia, Pediatric immunology department

    Brescia, Italy, 25213, Italy

  • St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection

    London, SE1 7EH, United Kingdom

  • The Johns Hopkins Hospital, Division of pediatric allergy and immunology

    Baltimore, Maryland, 21289, United States

  • UT Health Houston, Department of pediatrics, division of child & adolescent neurology

    Houston, Texas, 77030, United States

  • Universitary Hospital Virgen del Rocío

    Seville, 41013, Spain

  • University Children's Hospital Zürich - Eleonore Foundation

    Zurich, CH 8008, Switzerland

  • University Hospital Frankfurt, Pediatric and Adolescent Clinic

    Frankfurt, Germany, 60590, Germany

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, B152GW, United Kingdom

  • University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.